Objective To investigate the clinical application of anlotinib in a hospital and evaluate the rationality and safety of related medications,in order to standardize the clinical application of anlotinib.Methods To collect information on 106 patients with clinical application of amilorotinib in a county-level general hospital from January 1,2022 to June 30,2023,who received a total of 306 doses of amilorotinib-containing regimens,and to conduct a retrospective analysis of the reasonableness and safety of the clinical application of anlotinib.Results Among the 306 treatments,89 cases(29.08%)of medication were irrational,and the types of irrationality were 47 cases(15.36%)of irrationality in combination of medication,21 cases(6.86%)of over-indications,19 cases(6.21%)of irrationality in dosage,and 2 cases(0.65%)of prohibited use of medication.There were 358 cases of adverse drug reactions(ADR)found in these medical records.The top five organ-system injury were diseases of the digestive system(30.73%),Metabolic and Nutritional Diseases(16.48%),diseases of the blood and lymphatic system(13.41%),diseases of the cardiovascular system(9.22%)and bleeding(5.31%).Conclusion Some irrationality in the clinical use of anrotinib in the hospital,the hospital and relevant quality control department should prescribe and rationally use anlotinib standardize the instructions of anlotinib,the latest domestic and international guidelines and consensus,strengthen the monitoring of medication,evaluate the adverse reactions,and improving the safety of anrotinib.
维普
万方数据